Author:
Peró Marta,Casani Laura,Castells-Sala Cristina,Pérez Maria Luisa,Moga Naranjo Esther,Juan-Babot Oriol,Alserawan De Lamo Leticia,López-Chicón Patricia,Vilarrodona Serrat Anna,Badimon Lina,Porta Roda Oriol
Abstract
AbstractThe aims of this study were to evaluate the feasibility of the New Zealand White (NZW) rabbit for studying implanted biomaterials in pelvic reconstructive surgery; and to compare the occurrence of graft-related complications of a commercial polypropylene (PP) mesh and new developed human dermal matrix implanted at vaginal and abdominal level. 20 white female NZW rabbits were randomized into two groups, experimental group (human acellular dermal matrices-hADM-graft) and control group (commercial PP graft). In each animal, grafts were surgically implanted subcutaneously in the abdominal wall and in the vaginal submucosa layer for 180 days. The graft segments were then removed and the surgical and clinical results were analyzed. The main surgical challenges during graft implantation were: (a) an adequate vaginal exposure while maintaining the integrity of the vaginal mucosa layer; (b) to keep aseptic conditions; (c) to locate and dissect the breast vein abdominal surgery; and (d) to withdraw blood samples from the ear artery. The most abnormal findings during the explant surgery were found in the PP group (33% of vaginal mesh extrusion) in comparison with the hADM group (0% of vaginal graft extrusion), p = 0.015. Interestingly, macroscopic observation showed that the integration of the vaginal grafts was more common in the hADM group (40%) than in the PP group, in which the vaginal mesh was identified in 100% of the animals (p = 0.014). The NZW rabbit is a good model for assessing materials to be used as grafts for pelvic reconstructive surgery and vaginal surgery. Animals are easily managed during the procedures, including surgical intervention and vaginal mucosa approach. Additionally, hADM is associated with fewer clinical complications, as well as better macroscopic tissue integration, compared to PP mesh.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Abrams, A. et al. Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and faecal incontinence. Report of the International Scientific Committee. Neurourol Urodyn 37, 2271–2272. https://doi.org/10.1002/nau.23551 (2018).
2. Unger, C. A. & Barber, M. D. Vaginal mesh in pelvic reconstructive surgery: controversies, current use, and complications. Clin Obstet Gynecol 58(4), 740–753. https://doi.org/10.1097/GRF.0000000000000148 (2015).
3. Vaginal mesh: high vigilance restriction period: Immediate action required, all cases should be postponed if it is clinically safe to do so. https://www.rcog.org.uk/globalassets/documents/guidelines/safety-alerts/mesh-letter-to-acute-ceos-mds-july-2018.pdf.
4. FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices. https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-womens-health-orders-manufacturers-surgical-mesh-intended-transvaginal
5. Badylak, S. F., Freytes, D. O. & Gilbert, T. W. Reprint of: extracellular matrix as a biological scaffold material: structure and function. Acta Biomater 23(Suppl), S17-26. https://doi.org/10.1016/j.actbio.2015.07.016 (2015).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献